Table 1 The advances of bispecific/bifunctional antibodies targeting PD-1/PD-L1 signaling
From: The enhanced antitumor activity of bispecific antibody targeting PD-1/PD-L1 signaling
Targets | Agents | Maximum R&D stage | Original Drug Company/Authors |
|---|---|---|---|
TGFβ × PD-L1 | M7824 (Bintrafusp alfa) | Phase 3 | Merck KGaA |
YM101/BiTP | Phase 1/2 | Wuhan YZY Biopharma | |
SHR-1701 | Phase 3 | Hengrui Pharmaceuticals | |
BR102 | Phase 1 | BioRay Pharmaceutical | |
TQB-2858 | Phase 2 | Nanjing Shunxin Pharmaceutical | |
PM8001 | Phase 1/2 | Pumis Biotechnology | |
TST005 | Phase 1 | Suzhou Transcenta Therapeutics | |
TGFβ × PD-1 | JS201 | Phase 1/2 | Junshi Biosciences |
CD47 × PD-L1 | IBI322 | Phase 2 | Innovent Biologics |
PF-07257876 | Phase 1 | Pfizer Inc | |
6MW3211 | Phase 2 | Mabwell Bioscience | |
IMM2520 | Phase 1 | ImmuneOnco Biotechnology | |
BAT-7104 | Phase 1 | Bio-Thera Solutions | |
IBC0966 | Phase 1/2 | Beijing Sunho Pharmaceutical | |
VEGF × PD-1 | AK112 (Ivonescimab) | Application for market | Akeso Biopharma |
VEGF × PD-L1 | PM8002 | Phase 2/3 | Pumis Biotechnology |
B1962 | Phase 1 | Shanghai Tasly Pharmaceutical | |
HB0025 | Phase 2 | Zhejiang Huahai Pharmaceutical | |
4-1BB × PD-L1 | ABL503 | Phase 1 | ABL Bio |
PM1003 | Phase 1/2 | Pumis Biotechnology | |
PRS-344/S095012 | Phase 1/2 | Servier Bio-Innovation LLC | |
HK010 | Phase 1 | HankeMab | |
GEN1046 | Phase 1 | Genmab | |
LAG-3 × PD-L1 | IBI323 | Phase 2 | Innovent Biologics |
ABL501 | Phase 1 | ABL Bio | |
FS118 | Phase 1/2 | InvoX Pharma Limited | |
LAG-3 × PD-1 | INCA32459 | Phase 1 | Incyte Corporation |
Tebotelimab (MGD013) | Phase 3 | MacroGenics | |
RO7247669 (Tobemstomig) | Phase 2 | Hoffmann-La Roche | |
EMB-02 | Phase 1/2 | Shanghai EpimAb Biotherapeutics | |
CTLA-4 × PD-1 | QL1706 | Phase 2/3 | Qilu Pharmaceutical |
MGD019 (Lorigerlimab) | Phase 2 | MacroGenics, Inc | |
XmAb2071 (Vudalimab) | Phase 2 | Xencor | |
AK104 (Cadonilimab) | Approved listing (Cervical cancer) | Akeso Biopharma | |
MEDI5752 | Phase 1 | AstraZeneca PLC | |
CTLA-4 × PD-L1 | KN046 | Phase 3 | Jiangsu Alphamab Biopharmaceuticals |
TIM-3 × PD-L1 | LY3415244 | Phase 1 | Eli Lilly |
TIM-3 × PD-1 | AZD7789 | Phase 2 | AstraZeneca PLC |
RO7121661 (Lomvastomig) | Phase 2 | Hoffmann-La Roche | |
LB1410 | Phase 1 | L & L biopharma | |
PD-1 × PD-L1 | IBI318 | Phase 2 | Innovent Biologics |
LY3434172 | Phase 1 | Eli Lilly | |
TIGIT × PD-1 | AZD2936 (Rilvegostomig) | Phase 3 | AstraZeneca PLC |
IBI321 | Phase 1 | Innovent Biologics | |
TIGIT × PD-L1 | HLX301 | Phase 2 | Shanghai Henlius Biopharmaceuticals |
CD27 × PD-L1 | CDX-527 | Phase 1 | Celldex Therapeutics |